flow trial semaglutide kidney outcomes 2024 results chronic disease Kidney With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Kidney and Survival Outcomes with – Kidney and Survival Benefits of

Skriver C, Friis S, Knudsen LB, Catarig A-M, Clark AJ, Dehlendorff C, et al

According to CareEdge Ratings, Indias potential GLP-1 market is set to expand nearly five-fold from 1,000 crore to 1,200 crore in 2025 to approximately 4,500 crore to 5,000 crore by 2030

Pan-ERR activation by SLU-PP-332 **bypasses the need to stimulate PGC-1alpha via physical exercise**, making it the first credible "exercise mimetic" class candidate with complete pharmacokinetic profile

Absence of pain (non-tender) in a node that continues to enlarge, especially in adults over 40

Across all studies to date, a favorable tolerability and safety profile appropriate for chronic clinical use has been observed